Tag Archives: healthcare

Stonepeak-led Consortium to Acquire Estia Health

Stonepeak

 

SYDNEY – 27 May 2026 – Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced it has entered into a definitive agreement to acquire a majority stake in Estia Health, one of Australia’s leading residential aged care operators, from Bain Capital. The transaction marks a second investment for Volarae Living, Stonepeak’s social infrastructure platform in Australia and New Zealand, following its February 2026 investment in Aura Holdings.

Headquartered in Sydney, Estia Health is the second largest residential aged care operator in Australia, operating more than 90 homes across New South Wales, Queensland, South Australia, and Victoria, and caring for approximately 9,000 residents. Since its founding in 2014, Estia Health has thoughtfully expanded its footprint while continuing to invest in its employees, residents, and their families as part of its commitment to person-centered care.

“Residential aged care is, and will continue to be, an essential service and important component of Australia’s overall healthcare system, especially against the backdrop of an aging population,” said Darren Keogh, Senior Managing Director at Stonepeak. “We are thrilled to support Estia Health, a high-quality provider, build on its positive momentum, and even better serve older Australians.”

“I welcome the commitment to continuity for our residents, families and teams, and to ongoing investment in the capability of our people and systems so we can continue delivering high-quality care,” said Sean Bilton, CEO of Estia Health. “We look forward to working with Stonepeak, whose complementary experience and long-term investment approach support our strategy and build on our strong foundations. It remains our privilege to care for older Australians and support residents and their families at an extremely important time in their lives — and that will not change with our ownership.”

Stonepeak’s consortium partner in the transaction is Axight Capital Limited (Axight). The minority stake in Estia Health represents Axight’s second investment in Australia, further deepening its focus in the Asia Pacific Region.

“Estia Health has established itself as one of Australia’s leading residential aged care operators, underpinned by a strong reputation for quality care, operational excellence, and a deep commitment to residents, families and employees. We are delighted to be partnering with Stonepeak, whose significant expertise and proven experience across aged care and retirement living will be highly valuable as we support Estia Health’s continued growth,” said Jerry He and Mujtaba Hussain, Co-Managing Partners at Axight.

The transaction is expected to close in late 2026, subject to customary regulatory approvals. Terms of the transaction were not disclosed.

About Stonepeak
Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately A$125 billion (US$88 billion) of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, with a focus on downside protection and strong risk-adjusted returns. Stonepeak, as sponsor of private equity and credit investment vehicles, provides capital, operational support, and committed partnership to grow investments in its target sectors, which include digital infrastructure, energy and energy transition, transport and logistics, and real estate. Stonepeak is headquartered in New York with offices in Houston, Washington, D.C., London, Hong Kong, Seoul, Singapore, Sydney, Tokyo, Abu Dhabi, and Riyadh. For more information, please visit www.stonepeak.com.

Media Contacts

For Stonepeak:
Kate Beers / Maya Brounstein
corporatecomms@stonepeak.com
+1 (646) 540-5225

Jack Gordon
jack.gordon@sodali.com
+61 478 060 362

 

Categories: News

Tags:

Bain Capital to Exit Estia Health

BainCapital

SYDNEY – May 26, 2026 – Bain Capital, a leading global private investing firm, today announced it has entered into an agreement to sell Australian aged care provider Estia Health to alternative investment firm Stonepeak. Financial details were not disclosed.

Bain Capital acquired Estia Health in December 2023. The company is one of Australia’s leading residential aged care providers, operating homes across New South Wales, Queensland, Victoria, and South Australia. It is driven by its purpose to enrich and celebrate life together, delivered through the provision of high-quality residential aged care services to older Australians.

During Bain Capital’s investment period, Estia Health has grown from 73 homes with approximately 6,720 residents to 93 homes and approximately 9,250 residents. More than 14,000 people are now employed across the business.
The firm’s investment in Estia Health has been led by Australian-based Partners Mike Murphy, Charles Lawson, and Grace Mollard.

“Bain Capital is proud of the partnership we have built with Estia Health and its outstanding management team. We are deeply appreciative of the trust that families place in the company to care for their loved ones. We wish the entire team every success as they continue their important work,” Murphy said.

“During our ownership, we have supported Estia Health to deliver high quality of care and have invested heavily to grow its footprint and expand access to care. The significant increase in both the number of homes and residents served reflects our conviction in the company’s mission and our commitment to making a genuine difference in the lives of older Australians and their families,” Lawson added.

“We are proud to leave Estia Health an even stronger and more resilient business than when we first partnered together. The company is exceptionally well positioned to continue to play a leadership role in a critical sector. We have great confidence in the team and in Estia Health’s ability to continue delivering for residents, families, and the communities it serves,” Mollard concluded.

The transaction is expected to complete in late 2026, subject to standard regulatory approvals.

Barrenjoey and Gresham acted as financial advisors to Bain Capital. Allens acted as legal advisors.

ENDS

About Bain Capital

Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We create lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a collaborative culture that enables us to innovate, unlock opportunity, and deliver strong outcomes. Our global platform invests across Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. Across these focus areas, we bring deep sector expertise and broad capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $225 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X.

 

Media Contacts

Communications Director, Asia

 Australia

 Stuart Carson

Categories: News

Tags:

Ennov Announces Strategic Growth Investment from Bregal Sagemount and Ardian

No Comments
Ardian

Ennov (the “Company”), a global provider of end-to-end regulatory, quality, and clinical software solutions for life sciences and healthcare companies, today announced a strategic growth investment led by Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, with participation from Ardian, a global private investment firm. The investment will support the Company’s continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering.

Founded and headquartered in Paris, Ennov provides a unified compliance platform that serves as a centralized system of record for global life sciences organizations. The platform supports the management of content and data across key domains, including Regulatory, Quality, Commercial, Clinical, and Pharmacovigilance. Its integrated architecture and unified data model enable faster deployment, improved user adoption, consistent compliance, and AI-driven efficiency across global operations.

Developed over more than 25 years, Ennov’s software replaces fragmented point solutions and legacy infrastructure, enabling customers to manage complex regulatory requirements across global authorities such as the FDA and EMA within a single system. Today, the Company serves approximately 650 customers and over 500,000 users across 30 countries.

“We were looking for partners who understand the complexity of our customers’ environments and the opportunity ahead for integrated and AI-enabled software in life sciences. Sagemount and Ardian bring that perspective, and we look forward to continuing to build innovative solutions that support our customers’ most critical processes.” Olivier Pâris, Founder and CEO of Ennov

“Regulatory and quality workflows in life sciences are becoming increasingly complex, while the cost of managing them across disconnected systems continues to rise. Olivier and his team have spent more than two decades building a mission-critical solution that enables customers to not only manage but optimize their processes to achieve better business outcomes. We believe this opportunity is only accelerating with Ennov’s new AI products and we’re excited to support the Company in its next phase of growth.” Gene Yoon, Managing Partners at Sagemount

“Ennov represents exactly the kind of technology company we seek to support at Ardian Growth. We are excited to join forces with Bregal Sagemount, bringing together two leading US and European investment firms behind an exceptional management team. With its strong international footprint and rapidly expanding AI capabilities, Ennov is uniquely positioned to shape the future of regulatory, quality, and clinical software in life sciences worldwide.” Alexis Saada, Head of Growth at Ardian

With this growth investment, Gene Yoon, Curt Witte, and Harrison Brunelli from Sagemount and Alexis Saada from Ardian will be joining Ennov’s board of directors.

Ennov was advised by Veil Jourde. Sagemount was advised by Goodwin Procter LLP. Ardian was advised by Proskauer Rose LLP.

The transaction is expected to close in late Q2 2026, subject to regulatory approvals and customary closing conditions.

Ardian investment team: Alexis Saada, Olivier Roy, Alexandra Da Silva, Michelle Stitz

 

ABOUT ENNOV

Ennov provides a comprehensive software platform to manage the most demanding processes of life sciences organizations in a compliant and efficient way. With over 25 years of experience, Ennov’s cloud-based solutions cover Regulatory Affairs, Pharmacovigilance, Quality, Clinical, and Commercial. Dedicated to innovation and excellence, Ennov’s solutions are used by more than 650 companies and 500,000 users worldwide, helping them to bring their products to market faster while maintaining compliance with regulatory requirements. For more information, visit en.ennov.com or follow us on LinkedIn.

ennov.com

ABOUT BREGAL SAGEMOUNT

Bregal Sagemount is a leading growth-focused private capital firm with $11 billion of cumulative capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 90 companies in a variety of sectors, including software, data & information services, financial technology & services, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York and Palo Alto. For more information, visit www.sagemount.com or follow us on LinkedIn.

sagemount.com

ABOUT ARDIAN

In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world.
We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy.
Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry.
Ardian currently manages or advises $200bn for more than 1,920 clients worldwide across Private Equity, Real Assets, and Credit.
Ardian. Mastering change for lasting value.

ardian.com

Media contacts

Chief Sales and Marketing Officer at Ennov

Laure Bros

lbros@ennov.com 

Marketing & Communications Manager at Bregal Sagemount

Siqi Wu

siqi.wu@bregal.com 

ARDIAN

HEADLAND

ardian@headlandconsultancy.com 

Categories: News

Tags:

Verdane partners with ETERNO to scale its AI-native operating system across Germany’s outpatient care

Verdane Capital

ETERNO, a Berlin-based healthcare technology company, has secured a significant investment from Verdane for the expansion of its AI-native platform for outpatient care. The investment underscores the increasing importance of modernising one of Europe’s most fragmented and under-digitalised sectors.

Across Europe, healthcare systems remain heavily constrained by administrative inefficiencies. Doctors spend up to one full day per week on documentation, billing and other non-clinical tasks which reduces the time available for patient care.

At the same time, artificial intelligence is fundamentally reshaping outpatient healthcare and exposing the structural limitations of legacy software systems built for documentation and billing. As physicians operate in increasingly complex, data-rich environments, the next generation of healthcare infrastructure must evolve into open, interoperable and AI-native platforms capable of automating workflows, supporting clinical decision-making and orchestrating care operations in real time across the entire outpatient ecosystem.

Yet the underlying technology stack in practices remains fundamentally outdated. In Germany alone, more than 170,000 outpatient physicians still rely on fragmented legacy systems, with an estimated 97% of practice management software running on premise rather than in the cloud. Across Europe, around 2 million doctors work in outpatient care yet digital infrastructure remains highly fragmented and outdated.

“We believe outpatient care is undergoing one of the largest infrastructure shifts in decades – moving from fragmented legacy software toward open, AI-native operating systems that will redefine how care is delivered,” said Maximilian Waldmann, Founder and CEO of ETERNO.

ETERNO offers its AI-native operating system for doctors, ETERNO Cloud. The system is an open, fully integrated, cloud-based platform that automates administrative workflows end-to-end, from patient access and clinical documentation to billing and analytics.

With a team of more than 150 employees, the partnership with Verdane will allow ETERNO to scale its platform and to expand technological leadership, accelerate commercial rollout and pursue selective strategic acquisitions.

With Verdane, ETERNO has partnered with one of Europe’s leading growth investors, known for its strong track record in building and scaling category-leading platforms. Verdane brings deep operational expertise and a data-driven approach to value creation, supporting high-growth companies through their next phase of expansion.

Dominik Schwarz, Partner at Verdane, said: “Eterno is exactly in the sweet spot of Verdane’s investment focus. The company addresses a structural inefficiency in one of Germany’s most important and undersupplied markets, and has developed a product that resonates strongly with physicians. The combination of zero churn, a rapidly growing enterprise pipeline and a market that is still at the very beginning of cloud adoption underpins our conviction in the opportunity ahead. We look forward to supporting Max, Fredo and their team as they build a leading practice management platform in Germany.”

Maximilian Waldmann, Founder and CEO of ETERNO added: “For decades, outpatient care has been dominated by fragmented and closed legacy systems that were never designed for artificial intelligence. At the same time, healthcare generates vast amounts of valuable data that remain trapped across disconnected systems – limiting patient outcomes. At ETERNO, we believe the future of healthcare will be built on open and sovereign AI-native platforms that can securely connect workflows, medical records, devices and third-party apps across the ecosystem. Our ambition is to become the foundational infrastructure layer for outpatient care – enabling providers and AI builders to operate within one of Europe’s most complex and highly regulated markets. With Verdane, we have found a strong partner who combines long-term thinking with deep experience in scaling category-defining technology platforms.”

About Verdane

Verdane is a specialist growth buyout investment firm that partners with tech-enabled and sustainable businesses that help to digitalise and decarbonise the European economy. The flexible mandates of Verdane funds allow it to invest as a majority or minority control investor, replacement or growth capital, in single companies or in portfolios of companies.

Verdane has raised €10 billion in capital and its funds have made more than 200 investments in fast-growing businesses since 2003. Verdane’s team of over 180 investment professionals and operating experts is based out of Berlin, Copenhagen, London, Helsinki, Munich, Oslo and Stockholm and combines deep sector expertise with long-standing local networks and presence in core European markets.

Verdane is also a certified B Corporation, the most ambitious sustainability accreditation globally. The firm only backs businesses that pass its 2040 test, which indicates whether the company can thrive in a more sustainable future economy.

Verdane is partly owned by the Verdane Foundation, which is focused on two areas: climate change and more equitable and inclusive local communities.

About ETERNO

ETERNO was founded in 2019 by Maximilian Waldmann and Frederic Haitz and is a German healthcare technology company headquartered in Berlin. The company builds an AI-native operating system for doctors and therapists – a fully integrated, cloud-based platform that manages the entire patient journey, from patient access and clinical documentation to billing and analytics. By embedding artificial intelligence and deep system integration, ETERNO enables healthcare providers to significantly reduce administrative workload and improve care delivery. Today, more than 2,000 doctors across Germany rely on ETERNO Cloud in their daily practice operations.

Further information: http://www.eterno.group

Categories: News

Tags:

Het Gastenhuis opens new care home for people with dementia

NPM part of SHV

Het Gastenhuis opens new care home for people with dementia

NPM portfolio company Het Gastenhuis has opened a new residential care home in Meppel for people with dementia. With this new location, the organisation aims to provide residents with a familiar and personal living environment. The opening was attended by local alderman Klaas de Vries, founder and CEO Annemieke Bambach, and location managers Karola and Jorinde.

 

According to the initiators, the opening is not just about a new building, but about creating a home. “Opening a home is different from opening a building,” said the location managers. “A building consists of bricks, walls and furniture, but a home is created by the people who live, work and visit there. Through attention, warmth and small moments that give life meaning.”

 

The Meppel location focuses on residential care, allowing people with dementia to continue their daily lives as much as possible in a way that suits them. “With this location, we aim to offer exactly that. A place where people feel seen, where there is space for who someone is and everything that comes with that. Where residents can continue to live their lives in a way that suits them, with as much independence and trust as possible.”

 

The Meppel home is the 34th Het Gastenhuis location in the Netherlands. Earlier this year, a new location opened in Huizen, with additional openings planned this month in Elst and later this year in Eindhoven.

Categories: News

Tags:

Carlyle Acquires Knack RCM and EqualizeRCM to Create an AI-Native, Global Multi-Specialty Healthcare RCM Platform

Carlyle

WOODBRIDGE, N.J., AUSTIN, Texas, and MUMBAI, India – May 4, 2026 – Global investment firm Carlyle (NASDAQ: CG) today announced it has acquired a majority stake in Knack RCM (“Knack”) and EqualizeRCM (“Equalize”), two leading U.S. healthcare revenue cycle management (“RCM”) providers, to create an AI-native, global, multi-specialty RCM platform. Equity for the investment will come from investment funds affiliated with Carlyle Asia Partners VI (CAP VI) and Carlyle Asia Partners Growth II (CAPG II). The terms of the transaction are not disclosed. Rajiv Sharma, Founder of Knack RCM, and Nagi Rao, Founder of EqualizeRCM, will remain invested in the platform through a reinvestment of a portion of their proceeds.

 

Knack and Equalize are complementary healthcare RCM providers serving physician groups, durable medical equipment (“DME”) providers, rural hospitals, and other specialty provider segments. Together, they bring deep, specialty-specific expertise across DME, anaesthesia, eyecare, behavioural health, rural hospitals, urgent care, and multi-specialty physician groups.

 

The combined platform is expected to enhance operational scale and diversification, broaden the delivery footprint, strengthen leadership depth and help accelerate AI capabilities to enhance outcomes for clients. Knack contributes scaled, global delivery across the U.S., India, and the Philippines, anchored by an intelligent, end-to-end revenue engine powered by its orchestration platform, Workmate. EqualizeRCM complements this with its established delivery scale in the U.S. and India, alongside a proprietary payer enrollment platform and advanced AI-driven tools—such as Bill Smart for denial prediction and avoidance— that are purpose-built for hospitals, urgent care, and targeted specialty segments. Equalize’s AI-native platform, built on large language models and agentic AI, has demonstrated proven commercial traction, including the displacement of established, large-scale vendor contracts at leading DME manufacturers.

 

Kapil Modi, Partner at Carlyle India Advisors, said: “The U.S. healthcare revenue cycle market is growing rapidly, driven by margin compression, workforce shortages, and the shift to value-based care. Carlyle has significant experience in scaling RCM platforms to achieve market leadership and we believe Knack and Equalize stand out as leaders with their AI-native, specialty‑focused, and outcomes‑driven approach, which aligns well with the growing needs and demand in healthcare RCM.”

 

Rajiv Sharma, Founder, Knack RCM, said: “Carlyle has been a trusted partner to Knack, bringing not only capital but also valuable expertise in healthcare and RCM. The addition of Equalize is a progression of this partnership and strengthens the value we provide to our clients.”

 

Nagi Rao, Founder, EqualizeRCM, said: “Our clients, particularly rural hospitals and behavioural health providers, face immense pressure in sustaining margins and ensuring access to care. Partnering with Knack enables us to integrate our advisory expertise with their advanced analytics and global operations, to deliver more robust and tailored solutions. We are excited to work with Knack and Carlyle to drive wider adoption of our AI-native platform to support healthcare providers.”

 

Gautam Barai, CEO, Knack RCM, said: “Healthcare providers measure success by their ability to meet payroll, preserve services, and support their communities—not by the amount of automation deployed. Coming together with Equalize allows us to combine our strengths to tackle the most complex parts of the revenue cycle, including rural cost reports, DME intake, and challenging anaesthesia cases. For us, success is not about automating simple workflows but about addressing the most critical financial risks faced by our clients, which ultimately translates into improved financial health and better patient care.”

 

Amit Jain, Partner and Head of Carlyle India Advisors, concluded: “One of the core tenets of this investment is to build a scaled, strategically attractive physician and rural hospital RCM platform in a fragmented industry. Carlyle has a track record of executing similar strategies in sectors such as auto components and pharmaceuticals. This investment extends our India for the World thesis and builds on our experience investing in technology and tech-enabled services. We have invested in healthcare technology platforms including Indegene, Visionary RCM, and CorroHealth, and we will bring this expertise and execution capability to scale the combined Knack and Equalize platform.”

 

Carlyle intends to build on this platform strategy by pursuing additional opportunities in the RCM industry and will continue to seek to add synergistic assets with complementary offerings to the RCM platform.

 

***

 

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $477 billion of assets under management as of December 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,500 people in 27 offices across four continents. Further information is available at carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

About Knack RCM
Knack RCM is an AI-native, specialty‑focused revenue cycle management leader that helps healthcare organizations operating in complex clinical, financial and technology environments unlock the full value of reimbursement, safeguard margin and strengthen the delivery of care, so providers can better serve the communities that depend on them. Headquartered in Woodbridge, New Jersey, Knack RCM has over 8,000 employees across 10 delivery centers in India, the Philippines and the United States.

 

About EqualizeRCM
EqualizeRCM is a U.S.‑based revenue cycle management company serving physicians, hospitals, ambulatory surgery centers, laboratories and rural providers. The company is known for its work with Critical Access Hospitals, rural PPS Hospitals and Rural Health Clinics, providing specialized support in cost reports, reimbursement strategies and education forums that help clients navigate evolving payer and regulatory environments. The Company’s 1st Credentialing division is a leading provider of payor enrollment services across the nation.

 

 

Media Contacts

 

Carlyle
Lonna Leong
+852 9023 1157
lonna.leong@carlyle.com

Categories: News

Tags:

ARCHIMED Diagnostics, along with minority investor La Caisse, acquires Stago, a global leader in blood coagulation analysis

LaCaisse
  • Working with Stago management, ARCHIMED aims to expand sales and profits by building on gold-standard products in both developed and developing nations

ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has purchased alongside global investment group La Caisse (formerly CDPQ), Stago, a world leader for the analysis of blood coagulation issues (hemostasis). Stago develops and manufactures hemostasis equipment and reagents. It has unique expertise and a track record of innovation in this specialty.

Stago is held through ARCHIMED’s MED Platform II fund and was purchased from the founding Viret family by the Diagnostics team through an unspecified mix of equity and unitranche debt. Stago sells its products in 115 countries and posted revenues of €550 million in 2025. Based in Asnières-sur-Seine (greater Paris), Stago was founded in 1945 and is the only pure-play hemostasis analysis company in the world. Stago’s leadership team is taking a minority stake as part of the deal.

“In addition to financial muscle, ARCHIMED and La Caisse have the operational sophistication and discretion to help us grow at a pivotal moment in our company’s history,” says incumbent Stago CEO Jean‑Claude Piel, who retires from his post, becoming Chief of the Scientific and Technology Monitoring Committee. “ARCHIMED’s diagnostics expertise is key for accelerating the efficient rollout of a major, new generation of Stago products,” says Philippe Barroux, Stago’s CEO-elect. Barroux, a 38‑year Stago veteran, is currently CEO of operations in North America and China. “This partnership is all about reigniting innovation at Stago.”

ARCHIMED has made a total of eight diagnostics acquisitions, exiting two: Diesse, which became a pioneer in the development of cutting-edge systems for diagnosing inflammatory diseases and immune disorders in partnership with ARCHIMED; and Eurolyser, a point-of-care testing specialist, which saw profits rise more than two-fold and sales growth accelerate from the high single-digits to 25 percent annually during three years of ARCHIMED ownership.

“Our aim is to provide Stago with the resources it needs to accelerate global growth and to reinforce its leading position as a pure player with unrivalled expertise,” says ARCHIMED Managing Partner Vincent Guillaumot. “Stago has a pipeline of innovative products that should allow its revenues and profits to grow well above industry averages,” adds ARCHIMED Partner Antoine Faguer.

“Stago is a recognized leader in blood coagulation analysis, operating in a segment we know well, and serving a mission-critical role in medical diagnostics. Our investment alongside ARCHIMED reflects the value we place on partnerships and businesses with strong fundamentals,” said Martin Longchamps, Executive Vice-President and Head of Private Equity and Private Credit at La Caisse.

Working closely with Stago management, ARCHIMED will deploy its MedValue template – ARCHIMED’s levers for accelerating the growth of partnering companies via internationalization (often including bolt-on acquisitions), innovation and product range expansion.

Diagnostics is a primary investment sector for ARCHIMED, and one of the seven major sectors mapped through ARCHIMED’s MedSeg, its proprietary sector analysis tool covering 430 sub-segments of the global health industry. For the acquisition of Stago, ARCHIMED also deployed MedDiscover, a proprietary set of tools and processes permitting ARCHIMED to identify and effectively engage with leading companies operating in ARCHIMED’s prioritized sub‑sectors.

Stago is MED Platform II’s 10th investment. All of MED Platform II’s investments have been first-time leveraged buyouts for the companies acquired. MED Platform II, more than two times oversubscribed, closed on €3.5 billion in June, 2023. According to Preqin data, the fund is a top quartile performer for its vintage year as are all ARCHIMED funds. After the Stago transaction, MED Platform II is some 70 percent invested.

ABOUT ARCHIMED

www.archimed.group – With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

ABOUT LA CAISSE

At La Caisse, formerly CDPQ, we have invested for 60 years with a dual mandate: generate optimal long-term returns for our 48 depositors, who represent over 6 million Quebecers, and contribute to Québec’s economic development.

As a global investment group, we’re active in the major financial markets, private equity, infrastructure, real estate and private credit. As at December 31, 2025, La Caisse’s net assets totalled CAD 517 billion. For more information, visit lacaisse.com or consult our LinkedIn or Instagram pages.

La Caisse is a registered trademark of Caisse de dépôt et placement du Québec that is protected in Canada and other jurisdictions and licensed for use by its subsidiaries.

– 30 –

For more information

Categories: News

Tags:

McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

Apollo logo

IRVING, Texas, April 20, 2026 – McKesson Corporation (NYSE: MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of Apollo (“Apollo Funds”), under which Apollo Funds will acquire a minority ownership interest in McKesson’s Medical-Surgical Solutions (“MMS”) business. This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering.

Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson will retain operating control and majority ownership of MMS and consolidate the results for financial reporting. The transaction is subject to regulatory approvals and customary closing conditions.

“This transaction marks a key milestone in McKesson’s planned separation of MMS,” said Brian Tyler, chief executive officer of McKesson. “We are pleased to welcome Apollo as an important strategic and financial partner. Apollo’s experience in supporting complex carve-out and public market transactions will be additive as we position MMS for success, while maintaining McKesson’s financial and strategic flexibility. We look forward to working together to execute the separation in a manner that maximizes shareholder value, and establishing a well-capitalized, world-class medical surgical supply and solutions company.”

“MMS is a leading healthcare platform with a talented team and strong market position, playing a key role in healthcare supply chain resiliency across non-acute care settings,” said Apollo Partner Maxwell David and Managing Director Jeff Armstrong. “We believe the business is well positioned for continued growth, and that Apollo’s Hybrid platform enables us to provide flexible, scaled capital to support the next phase of development as MMS prepares to operate as a standalone company.”

Cautionary Statements

Statements in this press release about of the anticipated completion of Apollo’s investment in MMS, McKesson’s intent to separate MMS into an independent company, the planned initial public offering (“IPO”) of MMS, and the expected benefits of the transactions described, including anticipated timing, plans, expectations, commitments and intentions, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, risk factors include, but are not limited to: Apollo’s investment and the planned separation and IPO of MMS are contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; unanticipated business, market, governmental, or other developments could delay or prevent completion of Apollo’s investment, the separation, or the IPO, or cause any of the transactions to occur on less favorable terms; the transactions described are subject to conditions that may not be satisfied on the expected timeline, or at all, which could delay or prevent closing; we may be unsuccessful in achieving our strategic growth objectives; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events. We encourage investors to read the important risk factors described in McKesson’s most recent Form 10-K filed with the Securities and Exchange Commission.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

About Apollo

Apollo is a high-growth, global alternative asset manager. Apollo’s asset management business  seeks to provide its clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, Apollo’s investing expertise across its fully integrated platform has served the financial return needs of its clients and provided businesses with innovative capital solutions for growth. Athene, Apollo’s retirement services business, specializes in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Apollo’s patient, creative, and knowledgeable approach to investing aligns its clients, the businesses it invests in, its employees, and the communities it impacts, to expand opportunity and achieve positive outcomes. As of December 31, 2025, Apollo had approximately $938 billion of assets under management. To learn more, please visit www.apollo.com

Contacts

McKesson Corporation

Investors
Investors@McKesson.com

Media Relations
MediaRelations@McKesson.com

Apollo

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
Communications@apollo.com

Categories: News

Tags:

Eurobio Scientific signs definitive agreement to acquire CareDx’s transplant lab production division

IK Partners

Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market 

  • Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader
  • Creation of a global leading provider of kits for transplantation genomics
  • Acquisition of a 100% proprietary products portfolio
  • Deeper capabilities and larger scale with technological and commercial complementarities

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro medical diagnostics for transplantation, oncology and infectious diseases, today announces that it has entered into a definitive agreement to acquire the Lab Products division of CareDx, a US global precision medicine company focused on transplantation.

Through the acquisition of CareDx’s Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA”) typing and transplantation diagnostics. It combines Eurobio Scientific affiliate GenDx’s expertise in next-generation sequencing (“NGS”) assays, software and global commercial footprint, with CareDx’s portfolio of HLA-typing and transplant monitoring kits as well as its market leading customer service.

Strategic Rationale

This acquisition enables GenDx to offer a more comprehensive portfolio across the transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions. The combined entity will offer an expanded portfolio of molecular assays, reagents, and software, with the aim of enabling laboratories to streamline operations and improve clinical outcomes.

The integration of CareDx’s LabProducts division strengthens GenDx’s presence in key markets, including the United States, Europe and Asia-Pacific, while enhancing its ability to serve both research and clinical laboratories.

Key Highlights

  • Expanded Product Portfolio: Integration of CareDx’s HLA typing kits, including real-time polymerase chain reaction (“PCR”) and NGS-based solutions, with GenDx’s NGS assays and software platforms
  • Global Commercial Scale: Enhanced distribution capabilities and customer access across major transplantation markets
  • Technology Synergies: Acceleration of innovation in high-resolution HLA typing, hybrid capture, and transplantation monitoring workflows
  • Operational Efficiencies: Opportunities to streamline manufacturing and supply chain operations

Leadership Commentary

“This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation,” said Denis Fortier, CEO of Eurobio Scientific. “By combining our technological leadership with CareDx’s strong Lab Products portfolio, we are uniquely positioned to deliver comprehensive solutions to transplant laboratories worldwide.”

John Hanna, CEO of CareDx, added: “This transaction allows us to further focus on our core strengths in U.S.‑based Precision Medicine Diagnostic Testing Services and Patient and Digital Solutions, while ensuring that our Lab Products business continues to thrive under Eurobio’s leadership.”

Transaction Details

The transaction is subject to customary closing conditions and regulatory approvals. Under the terms of the agreement, Eurobio Scientific will acquire CareDx’s Lab Products business in cash for an equivalent of €145 million ($170 million), subject to customary adjustments.

Following closing, the LabProducts division will be integrated into GenDx’s operations, with a focus on maintaining continuity for customers, partners, and employees.

Eurobio Scientific is represented by TD Cowen and Kahn Partners in this transaction.  CareDx is represented by Rothschild & Co. and Fenwick.

Contacts

Groupe Eurobio Scientific
Denis Fortier, Chairman and CEO
Olivier Bosc, Deputy CEO/ CFO Tel. +33(0) 1 69 79 64 80

Actus
Mathieu Calleux
Investors Relations Tel. +33(1) 53 65 68 68 – eurobio-scientific@actus.fr

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy. Eurobio Scientific’s reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, “Pépites et Territoires” by AXA & NextStage AM investment program managed by NextStage AM as well as Jérome de Castrie. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Read More 

Categories: News

Tags:

Bain Capital and Evergreen Medical Properties Acquire Portfolio of Six Medical Outpatient Facilities in Atlanta Metropolitan Area

BainCapital

ATLANTA and BOSTON – April 9, 2026 – Bain Capital’s Real Estate team (“Bain Capital”) and Evergreen Medical Properties (“Evergreen”) today announced the acquisition of a medical outpatient building portfolio consisting of six assets totaling approximately 665,000 square feet in the Atlanta metropolitan area.  The private, off-market purchase was completed via a partnership between Bain Capital and Evergreen that focuses on acquiring, renovating, and operating mission-critical medical outpatient buildings.

The Class-A medical outpatient buildings are anchored by Northside Hospital, a leading, award-winning healthcare provider operating five acute-care hospitals and nearly 500 outpatient facilities across 25 counties in the Atlanta MSA. Northside leads the U.S. in newborn deliveries and is among Georgia’s top providers of cancer care, sports medicine, cardiovascular and surgical services. The portfolio is 93% leased and features other dynamic tenants spanning diverse specialties and high-acuity services.  The assets are located in “Pill Hill” and Alpharetta, two high-demand, affluent Atlanta submarkets.

“We’re pleased to expand our presence in Atlanta, a high-conviction market, as well as our relationship with Northside Hospital as we execute a value creation plan alongside the Evergreen team that enhances the facilities’ ability to better serve patients across the Atlanta area,” said Lukas Gregg, a Managing Director at Bain Capital.  “This transaction is an attractive opportunity to acquire a high-quality portfolio of mission-critical assets supported by strong market dynamics and we are grateful to be the new stewards of it.”

“We’re ecstatic Northside chose to expand our relationship with some of the health system’s most strategically important medical outpatient buildings,” said Joshua Richmond, President of Evergreen Medical Properties. “We look forward to working closely with Northside as we build upon Evergreen’s strong track record of aligning capital and healthcare partners through the stewardship of mission-critical real estate.”

The acquisition of these buildings follows the partnership’s recent purchase of a two-asset portfolio in Lawrenceville, GA, also anchored by Northside Hospital.  Bain Capital and Evergreen have curated a portfolio of institutional quality medical outpatient buildings in select markets throughout the U.S. and are actively seeking to grow its 2M square foot footprint.

Northside was advised by Realty Trust Group, a national healthcare advisory firm.

###

About Bain Capital Real Estate
Bain Capital Real Estate pursues investments in often difficult-to-access sectors underpinned by enduring secular trends that drive long-term demand growth for real estate assets and services. The Bain Capital Real Estate team has invested and committed over $10.7 billion of equity across multiple sectors as of September 30, 2025. Bain Capital Real Estate focuses on assets where the team applies its deep industry expertise to accelerate impact and drive operational improvements. Bain Capital Real Estate’s strategy aligns with the value-added investment approach that Bain Capital pioneered and leverages the firm’s global platform and significant experience across asset classes to further bolster its insights and sourcing capabilities. Bain Capital is one of the world’s leading private investment firms, with approximately $219 billion of assets under management. For more information, visit https://www.baincapitalrealestate.com.

About Evergreen Medical Properties  
Evergreen Medical Properties, with offices in both Denver and Atlanta, is a full-service real estate operating company that invests, leases and manages healthcare facilities across the United States. Evergreen uses a collaborative approach to invest in strategic healthcare real estate in order to align interests and build genuine relationships with health systems and providers.  Evergreen seeks to unlock capital, enhance the operating flexibility of its partners and create durable, long-term value in each of its healthcare real estate investments.

About Northside Hospital
The Northside Hospital healthcare system is one of Georgia’s leading healthcare providers with five acute-care hospitals in Atlanta, Canton, Cumming, Duluth, and Lawrenceville and nearly 500 outpatient locations across the state. Northside Hospital leads the U.S. in newborn deliveries and is among the state’s top providers of cancer care, sports medicine, cardiovascular, and surgical services. For more information, visit: www.Northside.com.

Categories: News

Tags: